PP01.19 Real-World Outcomes with Tarlatamab in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer
Back to course
Pdf Summary
Asset Subtitle
Sameer Deshmukh
Keywords
Tarlatamab
CD3 DLL3 bispecific T-cell engager
extensive-stage small cell lung cancer
ES-SCLC
Cytokine Release Syndrome
CRS
Immune Effector Cell-Associated Neurotoxicity Syndrome
ICANS
adverse effects
real-world safety
Powered By